CJC-1295 (No DAC)
- Growth hormone
The growth-hormone releaser — a stabilised fragment of GHRH that signals the pituitary to make its own growth hormone rather than replacing it.
Read the published research →What CJC-1295 (No DAC) does
This is the 29-residue active fragment of growth hormone-releasing hormone carrying four substitutions that exist purely to help it survive in plasma, the important one a D-alanine at position 2 that blocks the enzyme which otherwise inactivates natural GHRH within minutes. Because the signal enters upstream of the pituitary rather than replacing growth hormone, the body's own pulse pattern and feedback stay intact — pulse frequency and amplitude were unchanged in men given the DAC version. That DAC version, the same peptide carrying an albumin-binding linker, is a different molecule from what is sold as No DAC, and it is where the published human numbers come from: a single injection raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days against placebo in healthy adults, on a half-life of 5.8 to 8.1 days the linker-free version does not inherit. The characteristic effect of hitting this receptor is brief facial flushing, reported in 16 of 18 men given native GHRH, and reviewers list fluid retention, joint and muscle aches, prolactin and cortisol shifts, blood-sugar disturbance and injection-site reactions as effects across the class.
- Growth hormone support in adults
- Sleep depth and overnight recovery
- Lean mass and body composition
- Recovery between hard training blocks
- Age-related decline in growth hormone
Common areas of interest, not measured results. The findings below are the published data.
In two randomised, double-blind, placebo-controlled ascending-dose trials in healthy adults aged 21 to 61, single subcutaneous doses of the DAC-conjugated CJC-1295 raised mean growth hormone 2- to 10-fold for 6 days or more and mean IGF-1 1.5- to 3-fold for 9 to 11 days, half-life 5.8 to 8.1 days; after multiple doses IGF-1 stayed above baseline for up to 28 days. These results describe the conjugate, not the no-DAC peptide.13
In an uncontrolled before-and-after study in healthy men aged 20 to 40, each serving as his own control with no placebo group, a single injection of the DAC-conjugated CJC-1295 raised basal growth hormone 7.5-fold (P < 0.0001), mean growth hormone by 46% (P < 0.01) and IGF-1 by 45% (P < 0.001) one week later, while the frequency and magnitude of secretory pulses were unaltered.11
In normal male Sprague-Dawley rats given a single subcutaneous injection, the albumin-binding conjugate CJC-1295 produced a 4-fold greater growth hormone area under the curve over 2 hours than unmodified hGRF(1-29) and remained in plasma beyond 72 hours, with immunoreactivity on the serum albumin band by Western blot from 15 minutes. The authors attributed the advantage to the C-terminal maleimide that bioconjugates the peptide to albumin, which the no-DAC peptide lacks.1
For laboratory research use only. Not a drug, food, or cosmetic. Not for human or veterinary use, ingestion, or any form of consumption. Sold exclusively to qualified researchers.
